Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | CASP3 | P42574 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2829549 | 0.84 | PKM (0.55) | RXFP1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL2833925 | 0.82 | PKM (0.56) | RXFP1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL18449613 | 0.80 | RXFP1 (0.69) | RXFP1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL2833179 | 0.79 | PKM (0.50) | RXFP1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL2830406 | 0.78 | PKM (0.49) | RXFP1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL21004558 | 0.78 | RXFP1 (0.65) | RXFP1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL2833930 | 0.78 | MAOA (0.52) | RXFP1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL2832584 | 0.77 | ALDH1A1 (0.50) | RXFP1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL9686560 | 0.76 | MAOA (0.50) | RXFP1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL16651261 | 0.76 | RXFP1 (0.59) | RXFP1CYP1A2CYP2C9CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| US-9694006-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| EP-1945211-B1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-09-13 | — | — | US | disclosed |
| US-8207187-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| CN-101594866-A | The preparation of local usefulness | HELPERBY THERAPEUTICS LTD (GB) | 2009-12-02 | — | — | CN | disclosed |
| EP-2086542-A1 | TOPICAL FORMULATIONS | Helperby Therapeutics Limited (GB) | 2009-08-12 | — | — | EP | disclosed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| CN-101351203-A | Application of pyrroloquinoline compound in killing clinically latent microorganisms | HELPERBY THERAPEUTICS LTD (GB) | 2009-01-21 | — | — | CN | disclosed |
| WO-2008056151-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | RXFP1 886/4885CYP1A2 378/4885CYP2C9 1642/4885 |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | RXFP1 886/4885CYP1A2 378/4885CYP2C9 1642/4885 |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | RXFP1 886/4885CYP1A2 378/4885CYP2C9 1642/4885 |
| US-20100093691-A1 | TOPICAL FORMULATIONS | DPM1, SUCLG1, LSS | RXFP1 988/4885CYP1A2 73/4885CYP2C9 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.